ARTICLE | Company News
Genentech, ImmunoGen deal
May 9, 2005 7:00 AM UTC
DNA paid IMGN $2 million to renew for three years the companies' 2000 deal that gave DNA rights to test and use IMGN's Tumor-Activated Prodrug (TAP) technology with therapeutic antibodies. ...